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Increasing reports of the appearance of novel nonmultiresistant methicillin-resistant Staphylococcus aureus
MRSA (MRSA) strains in the community and of the spread of hospital MRSA strains into the community are
cause for public health concern. We conducted two national surveys of unique isolates of S. aureus from clinical
specimens collected from nonhospitalized patients commencing in 2000 and 2002, respectively. A total of 11.7%
of 2,498 isolates from 2000 and 15.4% of 2,486 isolates from 2002 were MRSA. Approximately 54% of the MRSA
isolates were nonmultiresistant (resistant to less than three of nine antibiotics) in both surveys. The majority
of multiresistant MRSA isolates in both surveys belonged to two strains (strains AUS-2 and AUS-3), as
determined by pulsed-field gel electrophoresis (PFGE) and resistogram typing. The 3 AUS-2 isolates and 10 of
the 11 AUS-3 isolates selected for multilocus sequence typing (MLST) and staphylococcal chromosomal
cassette mec (SCCmec) analysis were ST239-MRSA-III (where ST is the sequence type) and thus belonged to
the same clone as the eastern Australian MRSA strain of the 1980s, which spread internationally. Four
predominant clones of novel nonmultiresistant MRSA were identified by PFGE, MLST, and SCCmec analysis:
ST22-MRSA-IV (strain EMRSA-15), ST1-MRSA-IV (strain WA-1), ST30-MRSA-IV (strain SWP), and ST93-
MRSA-IV (strain Queensland). The last three clones are associated with community acquisition. A total of 14
STs were identified in the surveys, including six unique clones of novel nonmultiresistant MRSA, namely, STs
73, 93, 129, 75, and 80slv and a new ST. SCCmec types IV and V were present in diverse genetic backgrounds.
These findings provide support for the acquisition of SCCmec by multiple lineages of S. aureus. They also
confirm that both hospital and community strains of MRSA are now common in nonhospitalized patients
throughout Australia.
Methicillin-resistant Staphylococcus aureus (MRSA) was
first reported in Australia in 1968 (50). The emergence of
MRSA strains resistant to gentamicin was first noted in eastern
Australia in 1976, and outbreaks of hospital infection due to
multiresistant MRSA (mMRSA; see Materials and Methods
for the definition) occurred in the state of Victoria in the late
1970s and early 1980s (42, 46). mMRSA became endemic in
hospitals in the eastern Australian states in the late 1980s and
1990s, with some spread to hospitals in South Australia, the
Northern Territory, and Tasmania (33, 56, 57). However, these
strains did not become established in Western Australian hos-
pitals due to active screening and infection control policies (33,
44).
In the early 1990s nonmultiresistant MRSA (nmMRSA; see
Materials and Methods for the definition) were observed in
Western Australia, initially from indigenous people in remote
communities (58) but subsequently also in Perth, the state
capital. They became known as “WA-MRSA” (where WA
represents Western Australia), and although nmMRSA strains
from the community do not readily spread in hospitals, one of
the WA-MRSA strains has been responsible for a documented
outbreak of hospital-acquired infection (36, 49). An increase in
the proportion of nmMRSA strains was also seen in other
Australian states in the 1990s (33). Community-acquired
nmMRSA strains were observed in the eastern states, and
studies in Queensland and New South Wales showed a strong
association between community-acquired infection with
nmMRSA and Polynesian ethnicity. Isolates causing these in-
fections were identical by phage typing and pulsed-field gel
electrophoresis (PFGE) to those previously reported in Auck-
land, New Zealand (15, 34). Subsequently, a second strain has
been shown to be associated with community-acquired infec-
tion in Caucasians in Queensland (28).
The emergence of community-acquired nmMRSA has been
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reported in other parts of the world, including Canada (10),
the United States (16, 27, 31), France and Switzerland (59),
Denmark (13), and Finland (51). However, other nmMRSA
strains, such as EMRSA-15 and EMRSA-16, have been asso-
ciated with health care settings and have spread internationally
(9, 26). nmMRSA strains are generally believed to have orig-
inated in the community environment, but they may also in-
clude nonmultiresistant sporadic hospital strains that have
been taken into the community (3). In addition, the spread of
strains associated with the health care setting into the commu-
nity has been documented (9, 19, 60). Both the emergence of
novel community-acquired strains and the spread of health
care setting-associated strains of MRSA to the community are
causes for public health concern. The prevalence of MRSA in
the community must be taken into account in the formulation
of health care policy in areas such as antibiotic prescription
and infection control. The aim of this study was to establish the
proportion of MRSA strains among clinically significant out-
patient S. aureus isolates in all Australian states and territories,
to determine the genetic backgrounds of the MRSA strains,
and to determine if any previously undescribed strains are
causing infections in outpatients.
MATERIALS AND METHODS
Bacterial isolates. Isolates were collected from patients attending primary care
clinics, outpatient clinics, emergency departments, or other outpatient settings or
residing in long-term-care residential facilities. Twenty teaching hospital labora-
tories (THLs) and five private pathology laboratories (PPLs) in eight Australian
cities participated in the study. The locations of the laboratories were as follows:
two THLs and one PPL in Brisbane, Queensland; six THLs and one PPL in
Sydney, New South Wales; one THL in Canberra, Australian Capital Territory;
three THLs and one PPL in Melbourne, Victoria; one THL in Hobart, Tasma-
nia; three THLs and one PPL in Adelaide, South Australia; three THLs and one
PPL in Perth, Western Australia; and one THL in Darwin, Northern Territory.
Up to 100 consecutive clinical isolates of S. aureus were collected at all labora-
tories for each of two surveys, the first of which was conducted from 1 June 2000
to 30 April 2001 (the 2000 survey) and the second of which was conducted from
1 October 2002 to 16 March 2003 (the 2002 survey). Isolates from infection
control screening specimens were excluded, as were duplicate clinical isolates, as
determined by their antimicrobial susceptibility phenotypes.
Identification and susceptibility tests. S. aureus was identified by positive
results by at least two of three tests: the slide coagulase or latex agglutination,
tube coagulase, and heat-stable nuclease tests (21). Urease production was tested
by using Christensen’s urea slopes incubated for 24 h at 37°C (6). Susceptibility
testing was performed by agar dilution by the NCCLS methodology (32), except
that a single breakpoint concentration of each antimicrobial was used. Briefly,
the following antimicrobials were obtained from the manufacturers as reference
powders of assayed potency or in tablet form and were incorporated into agar
plates at the indicated concentrations: penicillin G, 0.125 mg/liter; oxacillin, 2
mg/liter; vancomycin, 2 mg/liter; teicoplanin, 2 mg/liter; rifampin, 1 mg/liter;
fusidic acid, 1 mg/liter; gentamicin, 4 mg/liter; chloramphenicol, 8 mg/liter; eryth-
romycin, 0.5 mg/liter; clindamycin, 0.5 mg/liter; tetracycline, 4 mg/liter; tri-
methoprim, 8 mg/liter; ciprofloxacin, 1 mg/liter; and mupirocin, 1 mg/liter. An
antibiotic-free control plate was included in each batch. The following control
strains were included in each batch: S. aureus ATCC 25923, S. aureus ATCC
29213, Staphylococcus epidermidis ATCC 14990, Escherichia coli ATCC 25922,
and Enterobacter cloacae ATCC 13047. Resistance was defined as growth on the
concentration tested; a fine haze was ignored for chloramphenicol, tetracycline,
and trimethoprim.
MRSA isolates were divided into two heterogeneous groups on the basis of
resistance to nine antibiotics: erythromycin, tetracycline, trimethoprim, gentami-
cin, rifampin, fusidic acid, ciprofloxacin, chloramphenicol, and mupirocin. Iso-
lates which were resistant to three or more of the antibiotics listed above were
defined as mMRSA, and those resistant to less than three were defined as
nmMRSA. The sources of the patient isolates were recorded in most cases.
Resistogram typing. Resistance testing was performed by disk diffusion against
a panel of six chemicals and dyes (54, 55): cadmium acetate (10 mM), sodium
arsenate (0.2 M), ethidium bromide (15 mM), propamidine isothionate (2%
[wt/vol]), mercuric chloride (HgCl2; 0.4 M), and phenylmercuric acetate (PMA;
5 mM).
Bacteriophage typing. Bacteriophage typing was performed by the method of
Blair and Williams (7) by using (i) the basic international set of 23 phages for S.
aureus (group I, phages 29, 52, 52A, 79, and 80; group II, phages 3A, 3C, 55, and
71; group III, phages 6, 42E, 47, 53, 54, 75, 77, 83A, 84, and 85; group V, phages
94 and 96; and miscellaneous, 81 and 95) (40), (ii) 3 experimental phages (phages
88, 90, and 187) (4), and (iii) the international MRSA set of 10 phages (phages
MR8, MR12, MR25, 30, 33, 38, M3, M5, 56B, and 622) (47). All phages were
used at 100 times the routine test dilution.
Coagulase gene typing. Coagulase gene restriction fragment length polymor-
phism (RFLP) typing was performed as described previously (14).
PFGE. Pulsed-field gel electrophoresis (PFGE) of chromosomal DNA was
performed as described previously (36) with a CHEF DR III system (Bio-Rad
Laboratories Pty. Ltd.). Chromosomal DNA patterns were examined visually,
scanned with a Fluor-S Multimager, and digitally analyzed by using Multi-Ana-
lyst/PC software (Bio-Rad Laboratories). PFGE patterns were grouped accord-
ing to the criteria of Tenover et al. (52) and by using a dendrogram similarity of
80% or greater to assign strain relatedness. S. aureus NCTC 8325 was used as the
size marker (41).
Chromosomal DNA preparation. Multilocus sequence typing (MLST) with the
chromosomal DNA of the isolates from the 2000 survey was performed as
described by Huygens et al. (17). Chromosomal DNA for MLST and staphylo-
coccal chromosomal cassette mec (SCCmec) typing of isolates from the 2002
survey was prepared either as described previously (23) or with a DNeasy Tissue
kit (Qiagen Pty. Ltd., Clifton Hill, Victoria, Australia).
MLST. MLST was performed with selected isolates as specified by Enright et
al. (11). The sequences obtained were compared with the sequences at the MLST
website (http://www.mlst.net/) to assign a sequence type (ST).
SCCmec typing. SCCmec was typed by PCRs that determined the class of mec
complex and the type of cassette chromosome recombinase (ccr) harbored by the
elements. Primers were used as described previously (23). Additional primers
included those that detected the class C2 mec complex (20) and ccrC (18) of the
type V SCCmec and forward primer mA (23) with reverse primer mI4 (5-TG
GACTCCAGTCCTTTTGC-3; this study) or mI2 (22) for investigation of the
novel SCCmec of isolate CH39.
RESULTS
A total of 2,498 isolates were tested in the 2000 survey, of
which 293 (11.7%) were resistant to oxacillin. In the 2002
survey, 2,486 isolates were tested, of which 384 (15.4%) were
resistant to oxacillin. The levels of resistance to individual
antibiotics were similar for methicillin-susceptible S. aureus
and MRSA strains in both surveys, with the exception that the
rates of resistance to both ciprofloxacin and clindamycin in-
creased by approximately 5% among MRSA isolates in 2002.
In 2000 all nmMRSA isolates were gentamicin susceptible,
while in 2002 four isolates (1%) were gentamicin resistant. The
proportions of specimens from various types of facilities were
similar in both surveys. Overall, 14% were from primary care
facilities, 47% were from emergency departments, 19% were
from outpatient clinics, 7% were from long-term residential
care facilities, and 13% were from other or unknown outpa-
tient sources. The overall proportions of MRSA strains that
were nmMRSA were similar for the two survey periods. How-
ever, there was considerable variation in the proportions of
MRSA and nmMRSA isolates throughout the country (Table
1).
Two hundred eighty MRSA isolates from the 2000 survey
(124 mMRSA isolates and 156 nmMRSA isolates) and 367
MRSA isolates from the 2002 survey (168 mMRSA isolates
and 199 nmMRSA isolates) were further characterized by re-
sistogram testing, urease determination, bacteriophage suscep-
tibility, coagulase RFLP analysis, and PFGE. The mMRSA
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isolates were made up of two major strains, designated AUS-2
and AUS-3 (Table 2). The characteristics of one isolate from
the 2000 survey were consistent with the published character-
istics of the Irish-2 strain (5), and the characteristics of three
isolates from the 2002 survey were consistent with those of the
previously described Irish-1 strain. The nmMRSA isolates
were grouped into 10 distinctive clones. Two were interna-
tional epidemic clones, EMRSA-15 and EMRSA-16, which
have been associated with hospital outbreaks (26). Two were
previously described community-associated clones, the south-
west Pacific (SWP) clone or the Western Samoan phage pat-
tern (WSPP) clone and WA-MRSA-1 (37, 59). The remainder
of the isolates were designated nmMRSA A to F (Table 2).
The distributions of the various strains in the two surveys at the
national level and for individual cities are shown in Table 3.
MLST was performed with 26 isolates from the 2000 survey
and 7 isolates from the 2002 survey (Table 4). The isolates
chosen from the 2000 survey represented strains with more
than one isolate, while in 2002 unique or sporadic isolates were
chosen along with one isolate each of the Irish-1 strain and
nmMRSA F. The results for clones described previously were
in accordance with those presented in previous publications
(12, 37, 59). All AUS-2 and AUS-3 isolates with the exception
of isolate AH1 were ST239; isolate AH1 was ST128, a single-
locus variant of ST239 with a gmk polymorphism. nmMRSA A
was indistinguishable from the previously described pulsotype
R or Queensland (QLD) clone, both of which are ST93 (28,
59).
SCCmec characterization was performed with all isolates
from the 2000 and 2002 surveys selected for MLST (Table 4).
Six SCCmec types, including two novel types, were identified
among the 14 STs. Of the 17 mMRSA isolates, 15 harbored the
type III SCCmec, and these comprised the ST239 isolates and
the related ST128 isolate. Of the two multiresistant ST8 iso-
lates, isolate RPH2 had the genetic background of the inter-
national epidemic Irish-2 clone (unpublished observations)
and harbored the pediatric type IV SCCmec (35). The other
isolate, isolate CH39, harbored a novel SCCmec that contained
TABLE 1. Distribution of MRSA and proportion of nmMRSA isolates in Australian cities
City
No. (%) of isolates
2000 survey 2002 survey
Total MRSA nmMRSA Total MRSA nmMRSA
Brisbane 300 23 (7.7) 17 (73.9) 300 37 (12.3) 25 (67.6)
Sydney 700 139 (19.9) 64 (46.0) 689 175 (25.4) 76 (43.4)
Canberra 100 5 (5.0) 5 (100) 100 8 (8.0) 3 (37.5)
Melbourne 400 42 (10.5) 4 (9.5) 399 46 (11.5) 6 (13.0)
Hobart 100 2 (2.0) 2 (100) 100 6 (6.1) 5 (83.3)
Adelaide 399 29 (7.3) 17 (58.6) 400 36 (9.0) 29 (80.6)
Perth 400 46 (11.5) 43 (93.5) 398 55 (13.8) 51 (92.7)
Darwin 99 7 (7.1) 6 (85.7) 100 21 (21.0) 10 (47.6)
National 2,498 293 (11.7) 158 (53.9) 2,486 384 (15.4) 205 (53.4)
TABLE 2. Summary of phenotypic and genotypic characteristics of mMRSA and nmMRSA strains in Australia
PFGE pattern Typical resistance patterna
Urease
test
result
Typical phage susceptibility
Coagulase
gene PCR-
RFLP pattern
Multiresistant
22 (AUS-2) TET, ERY, TMP, GEN, CIP  85, 88, 90; 47T, 87M; MR8, MR12, M3 24
24 (AUS-3) TET, ERY, TMP, GEN, CIP,
HgCl2, PMA
 87M//M3 24
Irish-2 ERY, TMP, CIP  85, 90; 90A, 87M 18
Irish-1 ERY, TMP, GEN, CIP  Non typeable 18
Sporadic Variable  variable Variable
Nonmultiresistant
EMRSA-15 ERY, CIP  Nontypeable 22
EMRSA-16 ERY, CIP  29; MR12 18
SWP Nil  WSPP1 (29, 52, 52A, 80, 3A, 54, 77, 81), WSPP2 (6, 42E, 47,
54, 77, 81; 67R)
24
WA-MRSA-1 ERY, FUS  1A (nontypeable), 1B, 52A, 55, 6, 42E, 47, 53, 54, 77, 83A, 85,
88, 90
20
nmMRSA A Nil  Nontypeable 32
nm MRSA B ERY  Nontypeable 258
nmMRSA C ERY  Variable Variable
nmMRSA D TET  Variable 18
nmMRSA E Nil  Variable Did not cut
nmMRSA F Nil  Variable No product
Sporadic Variable  Variable Variable
a TET, tetracycline; ERY, erythromycin; TMP, trimethoprim; GEN, gentamicin; CIP, ciprofloxacin; FUS, fusidic acid.
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type 2 ccr genes and a mec complex that contained intact mecA
and mecR1 genes but a truncated mecI gene in which only the
5 end was detected. Of the 16 nmMRSA strains tested, 12
harbored the type IV SCCmec that is found predominantly in
MRSA strains of community origin (34). Type IV SCCmec was
found in eight different genetic backgrounds (ST22, ST30, ST1,
ST93, ST73, ST8, ST80slv, and STnew). ST8, ST45, and ST152
isolates IMVS67, RPH74, and WCH100, respectively, har-
bored the type V SCCmec that has recently been described
(18) and reported in Australian community MRSA isolates
(35). A second novel SCCmec that harbored a class B mec
complex and the type5 ccrC gene was found in ST8 isolate
RBH87.
DISCUSSION
The increasing prevalence of MRSA infections in nonhos-
pitalized patients due to both the spread of health care setting-
associated strains into the community and the emergence of
unique community-associated strains is now a global problem.
The substantial and increasing proportions of MRSA isolates
in outpatient settings identified in these surveys are of clinical
concern. Approximately half of the MRSA isolates in the 2000
survey were due to known hospital-associated clones of ST239-
and ST128-MRSA-III (strains AUS-2 and AUS-3) and ST22-
MRSA-IV strain (EMRSA-15), with the prevalence of both of
these types of isolates slightly increasing in 2002. Of the re-
mainder, the majority were accounted for by nmMRSA clones
ST30 (SWP), ST1 (WA-MRSA-1), and ST93 (QLD), all of
which have been associated with well-documented community
acquisition (28, 34, 49).
The epidemic of health care setting-associated multiresistant
MRSA in eastern Australia began in Victoria in the late 1970s
(42). The epidemic strain, known as EA MRSA, spread to the
United Kingdom, where it was designated EMRSA-1 (53). The
earliest isolate of EA MRSA characterized by MLST, ANS46
(RM4), which was isolated in Melbourne in 1982, belongs to
ST239-MRSA-III (25, 38). As described above, the strains
prevalent in Australia at present, AUS-2 and AUS-3, belong to
the same lineage. ST239-MRSA-III is possibly the most suc-
cessful international epidemic clone of MRSA and is now
present in Australia, Europe, North America, South America,
and eastern Asia (2, 12, 39).
EMRSA-15 (ST22-MRSA-IV), an international clone of
nmMRSA associated with hospital infection, was first docu-
mented in Perth, Australia, in 1997, where it was detected
during the preemployment screening of health care workers
coming from the United Kingdom, Ireland, and eastern Aus-
tralia. It was responsible for outbreaks in four hospitals (45). It
is apparent from the 2000 and 2002 surveys that this clone is
now well established in Brisbane, Adelaide, Sydney, and Perth.
In Australia, community-associated nmMRSA strains were
first noted in remote communities in Western Australia in the
late 1980s (24, 49). The predominant clone, WA-MRSA-1
(ST1-MRSA-IV) (35), has since spread east throughout the
country and was detected in both surveys in all cities except
Canberra. Two other community-associated clones have be-
come established more recently, both of them initially in the
eastern part of the continent. An epidemic of community-
acquired nmMRSA associated with the Polynesian population
was noted in all eastern states and the Australian Capital
Territory in 1997 (8). This was subsequently shown to be due to
the SWP clone (ST30-MRSA-IV), which was initially detected
in New Zealand, where it was identified by phage patterns
WSPP-1 and WSPP-2 (15, 34, 48, 59). The 2000 survey con-
firmed its presence in all eastern capital cities (Brisbane, Syd-
ney, Canberra, Melbourne, and Hobart); the 2002 survey
TABLE 3. Distribution of MRSA isolates typed by PFGE in Australian cities in 2000 and 2002
Strain
No. (%) of isolates
National totals Brisbane Sydney Canberra
2000
(n  280)
2002
(n  367)
2000
(n  23)
2002
(n  33)
2000
(n  129)
2002
(n  169)
2000
(n  5)
2002
(n  8)
Nonmultiresistant
EMRSA-15 30 (10.7) 42 (11.4) 1 (4.3) 1 (3.0) 23 (17.8) 28 (16.6)
SWP 33 (11.8) 26 (7.1) 9 (39.1) 9 (27.3) 20 (15.5) 6 (3.6) 2 (40.0) 2 (25.0)
WA-MRSA-1 45 (16.1) 59 (16.1) 3 (13.0) 6 (18.2) 4 (3.1) 10 (5.9)
nmMRSA A 13 (4.6) 36 (9.8) 1 (4.3) 3 (9.1) 9 (7.0) 26 (15.4) 1 (20.0) 1 (12.5)
nmMRSA B 14 (4.9) 18 (4.9) 1 (4.3) 2 (6.1) 1 (0.6) 1 (20.0)
nmMRSA C 4 (1.4) 10 (2.7) 2 (1.6) 3 (1.8)
nmMRSA D 2 (0.7)
nmMRSA E 3 (1.1) 1 (0.3)
nmMRSA F 2 (0.7) 2 (0.5)
UK EMRSA-16 1 (0.3)
Sporadic 10 (3.6) 4 (1.1) 2 (8.7) 3 (2.3) 1 (0.6) 1 (20.0)
Subtotal 156 (55.7) 199 (54.2) 17 (73.9) 21 (63.6) 61 (47.3) 75 (44.4) 5 (100) 3 (37.5)
Multiresistant
AUS-2 90 (32.1) 123 (33.5) 5 (21.7) 9 (27.3) 61 (47.3) 88 (52.1) 5 (62.5)
AUS-3 18 (6.3) 39 (10.6) 3 (9.1) 1 (0.8) 2 (1.2)
Irish-2 1 (0.4)
Irish-1 3 (0.8) 2 (1.2)
Sporadic 15 (5.4) 3 (0.8) 1 (4.3) 6 (4.7) 2 (1.2)
Subtotal 124 (44.3) 168 (45.8) 6 (26.1) 12 (36.4) 68 (52.8) 94 (55.6) 0 5 (62.5)
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showed that it had spread westward to Adelaide, Darwin, and
Perth. The QLD clone (ST93-MRSA-IV) was first identified as
a cause of community-acquired infection in the Caucasian pop-
ulation in Ipswich, Queensland, in 2000 (28, 59). In 2000 it was
present in the eastern capitals (except Hobart) and Adelaide.
Its prevalence increased in the 2002 survey, and it had also
spread to Hobart and Perth.
MLST is particularly suited to the study of lineages of S.
aureus, including MRSA (11). S. aureus is clonal and is not
subject to frequent genomic recombination. Relying as it does
on the enumeration of the allelic profiles of housekeeping
genes spread throughout the core genome, MLST provides a
logical nomenclature for S. aureus clones: the ST precisely
defines a strain as having a unique and unambiguous allelic
profile and identifies those isolates that have descended from
the same recent common ancestor. MLST provides data that
are well suited to studies of the global epidemiology and the
population biology of bacterial pathogens (12).
The population structure of S. aureus has previously been
studied by a variety of techniques, including multilocus enzyme
electrophoresis, PFGE (29, 30), and MLST (11). We applied
MLST to a representative sample of our MRSA isolates and
found that they comprised 14 STs. Twelve STs fell into nine
clonal complexes, while two STs were singletons. All of the five
major clonal complexes previously associated with MRSA were
present (12). Three STs were represented in the group of
mMRSA isolates, namely, ST239, ST128, and ST8, all of which
belong to clonal complex 8 (CC8). MLST did not discriminate
between strains AUS-2 and AUS-3. However, a single-locus
variant of ST239 was found in an AUS-3 isolate (isolate AH1,
ST128). There was much more diversity among nmMRSA iso-
lates, among which 11 different STs were found, including the
four major clones already discussed. Furthermore, six of the
STs were unique to Australia, namely, STs 73, 93, 129, 75,
80slv, and new. The ST80slv-MRSA-IV isolates belong to the
same clonal complex as the ST80-MRSA-IV clone which has
been associated with community-acquired and hospital infec-
tions in a number of European countries (1, 13, 59). ST73 is a
single-locus variant of ST5, and so the ST73-MRSA-IV strain
(strain CH97) has a genetic background similar to that of the
pediatric clone; however, the SCCmec element is not of the
pediatric type (12). ST129 is a single-locus variant of ST78 and
ST150. Methicillin-resistant strains of both of the last two STs
are registered on the MLST database at http://www.mlst.net/.
The remaining three unique STs, STs 75, 93, and new, are
singletons and may represent new acquisitions of SCCmec.
All of the ST239 isolates and the related ST128 isolate har-
bored the type III SCCmec, which is the type most frequently
found in this pandemic lineage of health care setting-associ-
ated mMRSA (11, 38). It is most likely that these strains have
been acquired in the hospital environment and taken out into
the community by colonized patients. The ST8 Irish-2 strain
harbored the pediatric type IV SCCmec that has predomi-
nantly been reported in the pandemic ST5 pediatric clone of
MRSA (38). We have previously found the novel SCCmec
present in strain CH39 to be present in a strain from the
epidemic Irish-1 clone. Furthermore, the PFGE patterns of
strains CH39 and Irish-1 differ at only two bands (unpublished
observations), indicating that EMRSA isolates from the Irish-1
clone are also present in Australia.
The diversity of genetic backgrounds found to harbor the
type IV and V SCCmec types in this study suggests that, in
Australia, these two types of the cassette are well adapted for
the community environment and have probably been acquired
by methicillin-susceptible strains of S. aureus on multiple oc-
casions. The novel SCCmec harbored by strain RBH87
encodes the class B mec complex that is typical of type IV
TABLE 3—Continued
No. (%) of isolates
Melbourne Hobart Adelaide Perth Darwin
2000
(n  40)
2002
(n  39)
2000
(n  2)
2002
(n  6)
2000
(n  28)
2002
(n  36)
2000
(n  46)
2002
(n  55)
2000
(n  7)
2002
(n  21)
3 (10.7) 5 (13.9) 3 (6.5) 8 (14.5)
2 (5.0) 1 (2.6) 2 (5.6) 1 (1.8) 5 (23.8)
1 (2.5) 2 (5.1) 2 (100) 3 (50.0) 5 (17.9) 14 (38.9) 27 (58.7) 22 (40.0) 3 (42.9) 2 (9.5)
1 (2.5) 2 (33.3) 1 (3.6) 3 (8.3) 1 (1.8)
1 (2.6) 1 (3.6) 1 (2.8) 11 (23.9) 13 (23.6)
2 (7.1) 2 (5.6) 11 (23.9) 13 (23.6)
2 (7.1) 5 (9.1)
1 (3.6) 1 (2.8) 2 (4.3)
2 (28.6) 2 (9.5)
1 (1.8)
1 (2.6) 2 (7.1) 1 (2.8) 1 (2.2) 1 (14.3) 1 (4.8)
4 (10.0) 5 (12.8) 2 (100) 5 (83.3) 17 (60.7) 29 (80.6) 44 (95.7) 51 (92.7) 6 (85.7) 10 (47.6)
22 (55.0) 12 (30.8) 1 (16.7) 2 (7.1) 8 (38.1)
8 (20.0) 22 (56.4) 8 (28.6) 6 (16.7) 3 (5.5) 1 (14.3) 3 (14.3)
1 (2.2)
1 (1.8)
6 (15.0) 1 (3.6) 1 (2.8) 1 (2.2)
36 (90.0) 34 (87.2) 0 1 (16.7) 11 (39.3) 7 (19.4) 2 (4.3) 4 (7.3) 1 (14.3) 11 (52.4)
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TABLE 4. Phenotypic and genotypic characteristics of 33 isolates representative of strains of mMRSA and nmMRSA identified in Australia
in the 2000 and 2002 surveys
Isolate (survey yr) Resistance patterna
Urease
test
result
Phage susceptibility c
Coagulase
gene PCR-
RFLP
patternd
MLST
SCCmec type Straindesignationb
ST, allelic profile CC
Multiresistant
RPAH15
(2000)
TET, ERY, TMP,
GEN, CIP
 88, 85, (90); MR12, MR25,
56B; 56A, 56B, 56C,
67R, 87M
24 239, 2-3-1-1-4-4-3 8 III AUS-2
RPAH18
(2000)
TET, ERY, TMP,
GEN, CIP
 83A; MR8, MR12, MR25,
622, 56B; 56A, 56B;
56C, 67R, 87M
24 239, 2-3-1-1-4-4-3 8 III AUS-2
LVH25 (2000) TET, ERY, TMP,
GEN, CIP
 88, 85, 90; MR8, MR12,
622, 56B; 47T, 56A,
56B; 56C, 90A, 67R,
87M, 13M
24 239, 2-3-1-1-4-4-3 8 III AUS-2
CH10 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 88; 87M; MR12, MR25,
33, 38, M5
24a 239, 2-3-1-1-4-4-3 8 III AUS-3
IMVS51 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 85 24 239, 2-3-1-1-4-4-3 8 III AUS-3
GP35 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 85 24 239, 2-3-1-1-4-4-3 8 III AUS-3
IMVS20 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 88, 54, 85 24 239, 2-3-1-1-4-4-3 8 III AUS-3
FMC19 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 Nontypeable 24 239, 2-3-1-1-4-4-3 8 III AUS-3
RCH66 (2000) ERY, TMP,
GEN, CIP,
HgCl2, PMA
 Nontypeable 24 239, 2-3-1-1-4-4-3 8 III AUS-3
AH41 (2000) TET, ERY, TMP,
GEN, CIP,
RIF, HgCl2,
PMA
 Nontypeable 24 239, 2-3-1-1-4-4-3 8 III AUS-3
RDH81 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 Nontypeable 24 239, 2-3-1-1-4-4-3 8 III AUS-3
AH1 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 Nontypeable 24 128, 2-3-1-40-4-4-3 8 III AUS-3
FMC1 (2000) TET, ERY, TMP,
CIP, HgCl2,
PMA
 88, 85 24 239, 2-3-1-1-4-4-3 8 III AUS-3
AH13 (2000) TET, ERY, TMP,
GEN, CIP,
HgCl2, PMA
 Nontypeable 24 239, 2-3-1-1-4-4-3 8 III AUS-3
RPH2 (2000) ERY, CIP, TMP  (85), (90), (90A), 13M 18 8, 3-3-1-1-4-4-3 8 IV
(pediatric)
Irish-2
LIV79 (2002) ERY, GEN, CIP  Nontypeable 18 239, 2-3-1-1-4-4-3 8 III sporadic
CH39 (2002) ERY, TMP,
GEN, CIP
 Nontypeable Not tested 8, 3-3-1-1-4-4-3 8 Novel (i) mMRSA G
Nonmultiresistant
CH16 (2000) ERY, CIP  Nontypeable 22 22, 7-6-1-5-8-8-6 22 IV EMRSA 15
PAH58 (2000)  52, 52A, 80, 55, 54, 77, 84 24 30, 2-2-2-2-6-3-2 30 IV SWP
PAH1 (2000) ERY, MVP  55, 47, 54, 77, 84 24 30, 2-2-2-2-6-3-2 30 IV SWP
SJOG30 (2000) FUS  Nontypeable 20 1, 1-1-1-1-1-1-1 1 IV WAMRSAI
PC8 (2000) ERY  88, 52A, 6, 42E, 47, 53, 54,
83A, 85, 90
20 1, 1-1-1-1-1-1-1 1 IV WAMRSAI
RBH98 (2000)  Nontypeable 32 93, 6-64-44-2-43-55-51 Singleton IV QLD
RBH87 (2000) ERY, CIP  Nontypeable 258 129, 22-1-14-41-12-53-31 298 Novel (ii) nmMRSA
B
CH97 (2000) ERY  88, 29, 52A, 79, 47, 53, 54,
90
36 73, 1-4-27-4-12-1-10 5 IV nmMRSA
C
IMVS67 (2000) TET  88, 77, 83A, 84 18 8, 3-3-1-1-4-4-3 8 V nmMRSA
D
RPH74 (2000)  54 DNC 45, 10-14-8-6-10-3-2 45 V nmMRSA
E
RDH57 (2000)  52A, 79, 53 DNA 75, 36-3-43-34-39-52-49 New IV nmMRSA
F
RDH29 (2002) ERY  Nontypeable Not tested new, 36-new-43-34-new-
new-new
Singleton IV Sporadic
WCH100
(2002)
GEN  Nontypeable Not tested 152, 46-75-49-44-13-68-60 Singleton V Sporadic
RCH88 (2002) TET, FUS  Nontypeable Not tested 80slv, 1-3-1-14-11-27-10 80 IV Sporadic
RDH72 (2002)  Nontypeable Not tested 80slv, 1-3-1-14-11-27-10 80 IV Sporadic
Continued on following page
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SCCmec and the ccrC recombinase gene that is typical of type
V SCCmec, indicating that it may be a hybrid of the two types.
As a typing method, MLST provides good reproducibility
and the results between centers are comparable. The question
might be asked, what role does MLST play in epidemiological
studies? One application is the comparison of isolates col-
lected over a short period of time in different geographical
locations (43). This is the application that we adopted in this
study, and we found MLST to be sufficiently discriminatory for
all strains tested. Peacock et al. (43) indicated that the levels of
discrimination obtained by MLST and PFGE were comparable
if the isolates are grouped into PFGE types on the basis of two
or three band differences, which corresponds to the “closely
related” category by the criteria of Tenover et al. (52). The
combination of MLST and SCCmec typing proved particularly
useful in describing the variety of MRSA isolates present in
Australia. The diverse lineages described included both previ-
ously described international clones and new clones not previ-
ously associated with methicillin resistance. While SCCmec
typing provided no further discrimination of strains, the pres-
ence of SCCmec types IV and V in multiple clones argues
strongly for their acquisition by community S. aureus isolates
with genetic backgrounds more diverse than was previously
thought. The ability of some of these clones to spread widely in
a relatively short time is further cause for public health concern
and may require modification of guidelines for the treatment
and control of community-acquired infections due to S. aureus.
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